Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years

NCT00309634 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: 4 adjuvanted pandemic influenza candidate vaccines
BIOLOGICAL: 4 non-adjuvanted pandemic influenza candidate vaccines

Sponsor

GlaxoSmithKline